Kate Hermans

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.

Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.

83bar, Inc. is a private company that specializes in patient recruitment, engagement, and journey management. The company is based in Austin, TX. The company ensures that the right patient is delivered to the right place at the right time for clinical trials and commercialization requirements. The company was founded by Sue Hrim. The CEO is Bob Baurys.

Mid-Atlantic Diamond Ventures operates as an alternative investment manager. The company was founded in 2003 and is headquartered in Philadelphia, PA.

The Alzheimer's Association Delaware Valley Chapter provides information and resources for Alzheimer's and other dementias. The non-profit company is based in Philadelphia, PA. The organization is a part of the Alzheimer's Association national site, which offers information on Alzheimer's disease and dementia symptoms, diagnosis, stages, treatment, care, and support resources.

Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA.